Apomorphine in the treatment of Parkinson’s disease: A review

29Citations
Citations of this article
103Readers
Mendeley users who have this article in their library.

Abstract

Optimizing idiopathic Parkinson’s disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment.

Cite

CITATION STYLE

APA

Pessoa, R. R., Moro, A., Munhoz, R. P., Teive, H. A. G., & Lees, A. J. (2018, December 1). Apomorphine in the treatment of Parkinson’s disease: A review. Arquivos de Neuro-Psiquiatria. Associacao Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/0004-282x20180140

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free